Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections
Trial statusCompleted
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstituto de Investigación Sanitaria Gregorio Marañón
About this trial
The goal of this multicentre observational study is to analyse the treatment strategies and the outcomes for patients with S. maltophilia infections using target trial emulation methodology. The main question it aims to answer is:
• Does combined therapy achieve better results than monotherapy in treating S. maltophilia infections?
Researchers will compare groups receiving monotherapy and combined therapy to see if there are differences in all-cause 30-day mortality.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients
S. maltophilia infections
Different episodes if a new infection ocurred > 30 days since the index episode
Disqualifiers
isolates obtained from patients outside of hospital admission
microbiological or clinical colonization
hospitalizations shorter than 72 hours since the time zero
patients who died in the first 72 hours since the time zero or who were in imminent risk of death
Trial population
The selection criterion was the isolation of S. maltophilia in consecutive clinical samples from hospitalised adult patients, identified in microbiology laboratories between 2024 and 2025. The investigators first estimated the incidence of the S. maltophilia isolations per 1,000 admissions. Then, differenced episodes of infection defined if the treating physician considered of clinical significance the S. maltophilia isolation. Different infection episodes were considered from 30 days after the index episode.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
All-cause mortality
Time frame
At 30 days2
All-cause mortality
Time frame
At 60 daysSecondary outcomes
1
Frequency of complications
need for ICU admission and/or RRT, ECMO, recurrences, or in-hospital readmissions
Time frame
At 60 days2
Frequency of adverse events
Time frame
At 60 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: